文献速递治疗药物监测与药物基因组学特殊人群用药

津巴布韦乳腺癌队列中他莫昔芬的药物遗传学与药代动力学

Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort.
PubMed 文献 · Br J Clin Pharmacol · 2023-06-26

该研究在40例津巴布韦乳腺癌患者中探讨CYP2D6基因多态性与他莫昔芬活性代谢物endoxifen血浆浓度的关联,发现CYP2D6慢代谢等位基因*17和*29频率较高,55%患者endoxifen浓度低于治疗阈值5.97 ng/mL,且CYP2D6表型与活性评分显著关联endoxifen浓度及代谢比值。

要点

  • 津巴布韦人群中CYP2D6慢代谢等位基因*17和*29频率较高。
  • 55%患者endoxifen浓度低于治疗阈值5.97 ng/mL,多为中间代谢型。
  • CYP2D6表型与活性评分显著关联endoxifen浓度及代谢比值。

核心结论

  • CYP2D6基因多态性与津巴布韦乳腺癌患者endoxifen血浆浓度显著相关。
  • 该队列中多数中间代谢型患者endoxifen浓度低于治疗阈值。

研究设计与样本

  • 研究纳入40例津巴布韦乳腺癌患者,采用TaqMan基因分型和拷贝数测定确定CYP2D6基因型,并用LC-MS/MS定量他莫昔芬及其代谢物。

主要发现

  • CYP2D6慢代谢等位基因*17频率为15%,*29频率为18%。
  • endoxifen中位浓度为4.78 ng/mL。
  • 55%的患者endoxifen浓度低于5.97 ng/mL的治疗阈值,其中多为中间代谢型。
  • CYP2D6表型和活性评分与endoxifen血浆浓度显著相关(P = 0.0151)。
  • CYP2D6表型和活性评分与endoxifen/N-去甲基他莫昔芬比值显著相关(P = 0.0006)。

临床怎么用

  • 对津巴布韦乳腺癌患者可考虑CYP2D6基因分型以评估endoxifen暴露不足风险。
  • 中间代谢型患者可能需要更密切监测endoxifen浓度或调整治疗策略。

局限性

  • 样本量较小(n = 40),结论需更大队列验证。
  • 未报告临床结局数据,endoxifen浓度与疗效的关系未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tamoxifen is the most used hormonal therapy for oestrogen receptor-positive breast cancer. CYP2D6 is the main enzyme in the metabolic pathway of tamoxifen to endoxifen. Variations in endoxifen plasma concentrations are associated with CYP2D6 polymorphisms. This study aimed to determine the association between the CYP2D6 polymorphisms and endoxifen plasma concentrations in a cohort of Zimbabwean breast cancer patients (n = 40). TaqMan genotyping and copy number assays were done to determine CYP2D6 genotypes. Tamoxifen and metabolites were quantitated using LC-MS/MS. The population had high frequencies of the CYP2D6 reduced function alleles, *17 (15%) and *29 (18%). The median endoxifen concentration was 4.78 ng/mL, and in 55% of the patients, mostly intermediate metabolizers were below the endoxifen therapeutic threshold of 5.97 ng/mL. The CYP2D6 phenotypes and activity scores were significantly associated with endoxifen plasma concentrations (P = 0.0151) and with endoxifen to N-desmethyl-tamoxifen ratios (P = 0.0006).

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Mbavha BT, Thelingwani RS, Chikwambi Z, et al. Pharmacogenetics and pharmacokinetics of tamoxifen in a Zimbabwean breast cancer cohort. Br J Clin Pharmacol. 2023. PMID: 37337448. doi:10.1111/bcp.15827

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。